Healthcare / BiotechnologyNasdaqGM
$4.77
-0.16 (-3.25%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-86.3M · quality 60.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$997M
P/E
N/A
•EV/EBITDA
N/A
•ROE
1241.6%
↑Gross Margin
N/A
•Debt/Equity
-2.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-28.3%
FCF CAGR
—
FCF margin
-2345.1%
FCF / Net income
0.30x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.5M · net income $-354.1M · FCF $-105.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.5M | $4.5M | $9.2M | $17.5M | $12.2M |
| Net Income | $-354.1M | $-354.1M | $-184.2M | $-110.4M | $-54.3M |
| EBITDA | $-317.3M | $-317.3M | $-166.5M | $-102.0M | $-51.9M |
| EPS | -1.90 | -1.90 | -3.08 | -2.43 | -1.31 |
| Operating Margin | -2964.2% | -2964.2% | -1021.8% | -587.4% | -466.8% |
| Net Margin | -7899.6% | -7899.6% | -2002.7% | -631.8% | -445.6% |
| Balance Sheet | |||||
| Debt/Equity | -2.10 | -2.10 | -0.51 | -1.17 | 0.76 |
| Current Ratio | 3.16 | 3.16 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-105.1M | $-105.1M | $-86.3M | $-82.2M | $-45.5M |
| Returns | |||||
| ROE | 1241.6% | 1241.6% | 172.7% | 344.7% | -119.3% |
| Valuation | |||||
| P/B | — | — | — | — | 4.43 |
| Growth & Yield | |||||
| Revenue Growth | -51.3% | -51.3% | -47.4% | 43.5% | — |
| EPS Growth | 38.3% | 38.3% | -26.7% | -85.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+40.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.08 → -1.90
Residual
+40.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.